Abstract
During the past few decades, substantial progress in multidrug immunosuppressive and cytotoxic chemotherapeutic treatments have greatly improved the prognosis of most cancer patients. However, infectious complications due to acquired neutropenia have become a major medical issue, often requiring intensive care management. The infections may be lethal if empiric broad-spectrum treatment is not instituted at the first sign of infection. Although this is now considered standard practice, the selection and evaluation of the efficacy of antibiotic agents has generated considerable controversy for nearly 25 years. After reviewing some particularities of infection in neutropenic patients, this paper will discuss the options and suggest a comprehensive algorithm for the non-infectious diseases specialist.
Chapter PDF
Similar content being viewed by others
Keywords
- Antimicrob Agent
- Neutropenic Patient
- Febrile Neutropenic Patient
- Neutropenic Cancer Patient
- Streptococcal Bacteremia
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Mcgeer A, Feld R (1994) Epidemiology of infection in immunocompromised oncological patients. In: Balliere’s Clinical Infectious Diseases 1,pp 415–438
Hughes WT, Armstrong D, Bodey GP, et al (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–340
Schimpff SC (1995) Infections in cancer patients - diagnosis, prevention and treatment. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, pp 2266–2275
Talcott GP, Siegel RD, Finberg R, et al (1992) Risk assessment in patients with cancer with fever and neutropenia: A prospective two-center validation of a prediction rule. J Clin Oncol 10: 316–322
Talcott GP, Finberg R, Mayer RJ, et al (1988) The medical course of patients with cancer with fever and neutropenia. Arch Intern Med 148: 2561–2568
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328: 1323–1332
Bodey GP (1986) Infection in patients with cancer: A continuing association. Am J Med 81 (suppl 1A): 11–26
Calandra T, Cometta A (1991) Antibiotic therapy for Gram-negative bacteremia. Infect Dis Clin North Am 5: 817–834
Hathorn JW, Lyke K (1997) Empirical treatment of febrile neutropenia: Evolution of current therapeutic approaches. Clin Infect Dis 24 (suppl 2): S256–sS265
The EORTC International Antimicrobial Therapy Cooperative Group (1990) Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26: 569–574
Rolston KVI, Berkey P, Bodey GP, et al (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152: 283–291
Coullioud D, Van der Auwera P, Viot M, Lasset C (1993) Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. Cemic (french-belgian study club of infectious diseases in cancer). Support Care Cancer 1: 34–46
Cometta A, Zinner SH, De Bock R, et al (1995) Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 39: 445–452
Cometta A, Calandra T, Gaya H, et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40: 1108–1115
Winston DJ, Dudnick DV, Chapin M, Ho WG, Gale RP, Martin WJ (1983) Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med 143: 32–36
Bochud PY, Eggimann P, Calandra T, Van Melle G, Saghafi L, Francioli P (1994) Viridans strepto-coccal bacteremias in neutropenic cancer patients: clinical spectrum and risk factors. Clin Infect Dis 18: 25–31
Bochud PY, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 97: 256–264
Dybedal I, Lamvik J (1989) Respiratory insufficiency in acute leukemia following treatment with cytosine arabinoside and septicemia with streptococcus viridans. Eur J Haematol 42: 405–406
Karp JE, Merz WG, Hendricksen C, et al (1987) Oral norfloxacin for the prevention of gram- negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 106: 1–7
International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer (1994) Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. JAMA 272: 1183–1189
GIMEMA Infection Program (1991) Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 117: 7–12
Bow EJ, Manciell LA, Louie TJ, et al (1996) Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 125: 183–190
Anaissie E (1992) Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 14 (suppl 1): S43–S53
EORTC International Antimicrobial Therapy Cooperative Group (1989) Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 86: 668–672
Bodey G, Bueltmann B, Duguid W, et al (1992) Fungal infections in cancer patients: an inter-national autopsy survey. Eur J Clin Microbiol Infect Dis 11: 99–109
Schaffner A (1994) Prophylaxis and treatment of fungal infections in cancer patients. In: Balliere’s Clinical Infectious Diseases 1,pp 499–522
Winston DJ, Chandrasekar PH, Lazarus HM, et al (1993) Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double- blind, multicenter trial. Ann Intern Med 118: 495–503
Menichetti F, Del Favero A, Martino P, et al (1994) Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 120: 913–918
Powderly WG, Finkelstein D, Feinberg J, et al (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 332: 700–705
Novakova I, Donnelly JP, De Pauw B (1991) Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 35: 672–678
Gold D, Corey (1987) Acyclovir prophylaxis for herpes simplex virus infection. Antimicrob Agents Chemother 31: 361–367
Reusser P (1994) Prophylaxis and treatment of herpes virus infections in immunocompromised cancer patients. In: Balliere’s Clinical Infectious Diseases 1,pp 523–544
Jones RN, Thornsberry C, Barry AL (1984) In vitro evaluation of HR810, a new wide-spectrum aminothiazol a-methoxyimino cephalosporin. Antimicrob Agents Chemother 25: 710–718
EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317: 1692–1698
Klastersky J, Zinner SH, Calandra T, et al (1988) Empirical antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24: 535–545
Meunier F, Zinner SH, Gaya H, et al (1991) Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 35: 873–878
The EORTC International Antimicrobial Therapy Cooperative Group (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163: 951–958
EORTC International Antimicrobial Therapy Cooperative Group (1993) The efficacy and toxicity of single daily dose of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 119: 584–593
Karp JE, Hick JD, Angelopulos C, et al (1986) Empiric use of vancomycin during prolonged treatment induced granulocytopenia. Am J Med 81: 237–242
Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108: 30–35
Ramphai R, Bolger M, Obion DJ, et al (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36: 1062–1067
Edmond MB, Wenzel RP, Pasculle AW (1996) Vancomycin-resistant staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med 124: 329–334
Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE (1996) Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the united states. Antimicrob Agents Chemother 40: 2605–2609
Sanders JW, Powe NR, Moore RD, et al (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. J Infect Dis 164: 907–916
Eggimann P, Glauser MP, Aoun M, Meunier F, Calandra T (1993) Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 32 (Suppl B): 151–163
Ramphal R, Gucalp R, Rotstein C, Cimino M, Obion D (1996) Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 100: 83S–89S
Malik I A, Khan WA, Karim M, Aziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 98: 224–231
Freifeld AG, Pizzo PA (1996) The outpatient management of febrile neutropenia in cancer patients. Oncology 10: 599–612
Escalante CP, Rubenstein EB, Rolston KV (1997) Outpatient antibiotic therapy for febrile episodes in low-risk neutropenic patients with cancer. Cancer Invest 15: 237–242
Freifeld A, Pizzo P (1997) Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 16: 140–146
Cometta A, Baumgartner JD, Lew D, et al (1994) Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in non- neutropenic patients. Antimicrob Agents Chemother 38: 1309–1313
The meropenem study group of Leuven (1995) Equivalent efficacies of meropenem and ceft-azidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 36: 185–200
Santolaya ME, Villarroel M, Avendano LF, Cofre J (1997) Discontinuation of antimicrobial therapy for febrile, neutropenic children with cancer: a prospective study. Clin Infect Dis 25: 92–97
Clift RA, Sanders JE, Thomas ED, Buckner CD (1978) Granulocyte transfusions for the prevention of infection in patients receiving bone-marrow transplant. N Engl J Med 298: 1052–1057
Strauss RG, Conett JE, Gale RP, et al (1981) A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 305: 597–638
Cohen J, Heumann D, Glauser MP (1995) Do monoclonal antibodies and anticytokines still have a future in infectious diseases? Am J Med 99: 45S–52S
Cohen J, Carlet J (1996) Intersept: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med 24: 1431–1440
Fisher CJ Jr, Agosti JM, Opal SM, et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:fc fusion protein. The soluble tnf receptor sepsis study group. N Engl J Med 334: 1697–1702
Gardner P, Schaffner W (1993) Immunization of adults. N Engl J Med 328: 1252–1258
Fedson DS (1994) Adult immunization. Summary of the national vaccine advisory committee report. JAMA 272: 1133–1137
American society of clinical oncology (1994) Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508
Boogaerts M, Cavalli F, Cortes-Funes H, et al (1995) Granulocyte growth factors: achieving a consensus. Ann Oncol 6: 237–244
Freifeld A, Pizzo P (1995) Colony-stimulating factors and neutropenia: intersection of data and clinical relevance. J Natl Cancer Inst 87: 781–782
Pizzo PA (1995) Empiric therapy and prevention of infection in the immunocompromised host. In: Mandell GL, Bennett JE, Dolin R (eds) Principles and practice of infectious diseases. 4th ed. Churchill Livingstone, New York, pp 2686–2696
EORTC International Antimicrobial Therapy Cooperative Group (1984) Trimethoprim-sulfa-methoxazole in the prevention of infection in neutropenic patients. J Infect Dis 150: 372–379
Maschmeyer G (1993) Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts. Drugs 45 (Suppl 3): 73–80
Cometta A, Calandra T, Bille J, Glauser MP (1994) Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330: 1240–1241
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Eggimann, P. (1998). Management of Fever in Cancer Patients with Acquired Neutropenia. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 1998. Yearbook of Intensive Care and Emergency Medicine, vol 1998. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72038-3_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-72038-3_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63798-1
Online ISBN: 978-3-642-72038-3
eBook Packages: Springer Book Archive